Brenus Pharma
Created in 2014
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
26 2,492Activities
Technologies
Entity types
Location
Lyon, France
Lyon
France
Employees
Scale: 2-10
Estimated: 14
SIREN
802549030Engaged corporates
20
6 10Added in Motherbase
1 year, 2 months ago
biotech Value proposition
Tumor-antigen focused immunotherapies anticipating tumor plasticity, resistance to treatments and relapses ✔️🟣
Brenus Pharma, french private start-up in biotechnology based in Lyon, develops a platform technology to deliver first-in-class tumor-antigen focused immunotherapy.
The STC (Stimulated Tumor Cells) Technology allogeneic platform deliver STC drug product, in 3 major steps:
🟣 Cell Selection to mimic tumor heterogeneity & resistance capacities of the selected indication.
🟣 In vitro induction and overexpression of resistances marker by stimulation with Standard of care and Rx.
• 100+ cancer related surface proteins over expressed
• Cross-matching human tumoral biopsy databases
• Covering 3 categories of targets (Tumor Specific - Resistances to treatment - Tumor Plasticity)
🟣Tag of this resistances markers by Haptenization process, to make it visible by patient’s immune system.
Its mimic patient's relapsing conditions in vitro and educates patient's immune system to recognize cancer-related antigens driven by relapse mechanism when it will be injected in combination with current treatment.
👉 Like a therapeutic vaccine, STC product anticipates risks of tumor escape and the STC Platform answers huge unmet need in solid tumor by addressing limits of current treatment.
—————————————————
📢 Brenus has initiated a solid internal knowledge thanks to this collaboration between J.Gardette, co-Founder and renowned healthcare entrepreneur, DG at BIOCORP (health-tech company specialized in the design, development, and manufacturing of innovative medical devices) and B.Pinteur PharmD, co-Founder & CSO, specialized in innovative cellular therapies and founder of BioElpida (Biotechnology company specialized in innovative therapies’ manufacturing). Joined by P. Bravetti PharmD, HEC, CEO, Medical & Marketing expert with previous international experiences at Roche, Servier and Takeda Oncology; their knowledge has already proven its efficacy by overcoming many challenges within a competitive landscape & immuno-oncology technological constraints.
oncology, cancer, immune-therapy, innovation, cell therapy, I/O, healthtech, biotech, and cancervaccineOriginal language
Tumor-antigen focused immunotherapies anticipating tumor plasticity, resistance to treatments and relapses ✔️🟣
Brenus Pharma, french private start-up in biotechnology based in Lyon, develops a platform technology to deliver first-in-class tumor-antigen focused immunotherapy.
The STC (Stimulated Tumor Cells) Technology allogeneic platform deliver STC drug product, in 3 major steps:
🟣 Cell Selection to mimic tumor heterogeneity & resistance capacities of the selected indication.
🟣 In vitro induction and overexpression of resistances marker by stimulation with Standard of care and Rx.
• 100+ cancer related surface proteins over expressed
• Cross-matching human tumoral biopsy databases
• Covering 3 categories of targets (Tumor Specific - Resistances to treatment - Tumor Plasticity)
🟣Tag of this resistances markers by Haptenization process, to make it visible by patient’s immune system.
Its mimic patient's relapsing conditions in vitro and educates patient's immune system to recognize cancer-related antigens driven by relapse mechanism when it will be injected in combination with current treatment.
👉 Like a therapeutic vaccine, STC product anticipates risks of tumor escape and the STC Platform answers huge unmet need in solid tumor by addressing limits of current treatment.
—————————————————
📢 Brenus has initiated a solid internal knowledge thanks to this collaboration between J.Gardette, co-Founder and renowned healthcare entrepreneur, DG at BIOCORP (health-tech company specialized in the design, development, and manufacturing of innovative medical devices) and B.Pinteur PharmD, co-Founder & CSO, specialized in innovative cellular therapies and founder of BioElpida (Biotechnology company specialized in innovative therapies’ manufacturing). Joined by P. Bravetti PharmD, HEC, CEO, Medical & Marketing expert with previous international experiences at Roche, Servier and Takeda Oncology; their knowledge has already proven its efficacy by overcoming many challenges within a competitive landscape & immuno-oncology technological constraints.
Brenus Pharma
https://brenus-pharma.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 | SATT AxLR | Other 25 Apr 2024 | | |
 BioValley France Public business cluster, Biotechnology, French Cluster, Biotechnology Research | BioValley France Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 25 Apr 2024 | | |
 Mazars Consulting, audit, Accounting | Mazars Consulting, audit, Accounting | Other 23 Apr 2024 | | |
 RaiseLab Business Consulting and Services | RaiseLab Business Consulting and Services | Other 26 Apr 2024 | | |
 PMT Public business cluster, French Cluster, Civic and Social Organizations | PMT Public business cluster, French Cluster, Civic and Social Organizations | Other 2 Apr 2024 | | |
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 4 Apr 2024 | | |
 Agence Economique Régionale Bourgogne-Franche-Comté - AER BFC / AERBFC Government Administration | Agence Economique Régionale Bourgogne-Franche-Comté - AER BFC / AERBFC Government Administration | Other 22 Mar 2024 | | |
 | Agence régionale de santé (ARS) Auvergne-Rhône-Alpes | Other 3 Mar 2024 | | |
 | Ministère de la Santé | Other 3 Mar 2024 | | |
 Assurance Maladie Insurance, Government Administration | Assurance Maladie Insurance, Government Administration | Other 3 Mar 2024 | | |